



IFW

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of

Annie ANDRIEUX et al.

Application No.: 10/586,486

Filed: July 20, 2006

Docket No.: 128765

For: USE OF EPOTHILONES IN THE TREATMENT OF NEURONAL CONNECTIVITY
DEFECTS SUCH AS SCHIZOPHRENIA AND AUTISM

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

Pursuant to 37 CFR §1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

- ☒ 1. This Information Disclosure Statement is being filed (a) within three months of the U.S. filing date of this non-CPA application, OR (b) before the mailing date of a first Office Action on the merits in the present application. No certification or fee is required.
- ☒ 2. Relevance of one or more non-English language reference is discussed in the present specification. See References 2, 3, 7 and 9-11.
- ☒ 3. In accordance with 37 CFR §1.98(a)(2)(ii), copies of any U.S. patents and patent application publications are not attached.

- ☒ 4. An English language Abstract of one or more non-English language reference is attached hereto. See References 2, 3, 7 and 9-11.

Respectfully submitted,



William P. Berridge
Registration No. 30,024

Tarik M. Nabi
Registration No. 55,478

WPB:TMN/cdk

Date: September 7, 2006

OLIFF & BERRIDGE, PLC
P.O. Box 19928
Alexandria, Virginia 22320
Telephone: (703) 836-6400

**DEPOSIT ACCOUNT USE
AUTHORIZATION**

Please grant any extension
necessary for entry;
Charge any fee due to our
Deposit Account No. 15-0461

Form PTO-1449
(REV. 1/06)US Dept. of Commerce
PATENT & TRADEMARK OFFICEATTY DOCKET NO.
128765APPLICATION NO.
10/586,486INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)APPLICANT(S)
Annie ANDRIEUX et al.FILING DATE
July 20, 2006

GROUP

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number	Date	Name
	1	2003/0203929 A1	10/30/2003	GHOSH

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number	Date	Country	With English Abstract	With English Translation
	2	WO 98/22461	05/28/1998	WIPO	X	
	3	WO 99/07692	02/18/1999	WIPO	X	
	4	WO 99/02514	01/21/1999	WIPO		
	5	WO 99/67252	12/29/1999	WIPO		
	6	WO 00/50423	08/31/2000	WIPO		
	7	WO 02/21712 A1	03/14/2002	WIPO	X	
	8	WO 00/66589	11/09/2000	WIPO		
	9	WO 01/81341 A2	11/01/2001	WIPO	X	
	10	WO 00/49021	08/24/2000	WIPO	X	
	11	DE 198 21 954 A1	11/19/1998	GERMANY	X	

OTHER DOCUMENTS

Examiner Initials	Cite No.	(Including Author, Title, Date, Pertinent Pages, etc.)
	12	Andreasen, Nancy C., "Schizophrenia: the fundamental questions," Brain Research Interactive, Brain Research Reviews, Vol. 31, 106-112 pp, (2000).
	13	Frankle, W. Gordon et al., "The Synaptic Hypothesis of Schizophrenia," Neuron, Vol. 39, 205-216 pp, (2003).
	14	Jamain, Stephane et al., "Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism," Nature Genetics, Vol. 34, 27-29 pp, (2003).
	15	Andrieux, Annie et al., "The suppression of brain cold-stable microtubules in mice induces synaptic defects associated with neuroleptic-sensitive behavioral disorders," Genes & Development, Vol. 16, 2350-2364 pp, (2002).
	16	Kay, Stanley R. et al., "The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia," Schizophrenia Bulletin, Vol. 13, No. 2, 261-276 pp, (1987).
	17	Lindenmayer, Jean-Pierre et al., "Five-Factor Model of Schizophrenia Initial Validation," Journal of Nervous and Mental Disease, Vol. 182, No. 11, 631-638 pp, (1994).
	18	Mirmics, Karoly et al., "Analysis of complex brain disorders with gene expression microarrays: schizophrenia as a disease of the synapse," Trends in Neurosciences, Vol. 24, No. 8, 479-486 pp, (2001).

EXAMINER

DATE CONSIDERED

Examiner: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.